Role of SSA in the Management of Multiple Type 1 Gastric Neuroendocrine Neoplasms

#1593

Introduction: Type 1 g-NENs associated with autoimmune chronic atrophic gastritis have high risk of recurrence but rare metastasis. Most type 1 patients are managed by endoscopic approach. The clinical benefit of somatostatin analogues (SSA) for type 1 g-NENs is controversial.

Aim(s): To evaluate the efficacy and safety of octreotide LAR in the treatment of multiple type 1 g-NENs.

Materials and methods: From January 2012 to December 2015, A total of 74 pts with type 1 g-NENs were referred to our center (China-Japan Friendship Hospital, Beijing), among them five pts with multiple, small lesions were treated with octreotide LAR (20mg im q28d) for 12 months. After 6 and 12 months of SSA therapy, all the pts underwent gastroscopy with multiple biopsies in the antrum, fundus, body mucosa and the polypoid lesions. The serum gastrin and CgA levels were also determined.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tan H

Authors: Li Y, Dou D, Tan H,

Keywords: SSA, gastric nen, type 1,